Association of progesterone receptor status with histopathological grading in patients with intracranial meningioma
DOI:
https://doi.org/10.18203/2349-2902.isj20261165Keywords:
Intracranial meningioma, Progesterone receptor, WHO grading, Histopathology, ImmunohistochemistryAbstract
Background: Intracranial meningioma is a common primary brain tumor. Although most are benign, recurrence and variable behavior remain concerns. While World Health Organization (WHO) histopathological grading is an established prognostic tool, it does not always accurately predict tumor behavior. Progesterone receptor (PR) expression may serve as an additional prognostic marker. Objective of the study was to assess the association between progesterone receptor status and histopathological grading in patients with intracranial meningioma.
Methods: This cross-sectional observational study was conducted in the Department of Neurosurgery, Bangladesh Medical University, Dhaka, Bangladesh from June 2018 to March 2020. A total of 35 patients with histologically confirmed intracranial meningioma were included. Clinical and radiological data were collected using a structured data sheet. Tumors were graded according to WHO classification. Progesterone receptor status was evaluated by immunohistochemistry and categorized based on percentage of nuclear positivity. Data were analyzed using statistical package for the social sciences (SPSS) version 22, and associations were tested using Fisher’s exact test. A p value <0.05 was considered statistically significant.
Results: Among 35 patients, 88.57% had WHO grade I and 11.43% had grade II meningioma. A significant association was found between PR status and histopathological grade (p=0.013). Lower PR expression was more common in grade II tumors. No significant association was observed between PR status and tumor size.
Conclusions: Progesterone receptor status is significantly associated with histopathological grading and may serve as an additional prognostic marker in intracranial meningioma.
References
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17:iv1-62.
Alexiou GA, Gogou P, Markoula S, Kyritsis AP. Management of meningiomas. Clin Neurol Neurosurg. 2010;112:177-82.
Maharjan L, Neupane Y, Pradhan B. Primary atypical meningioma of the nasal cavity: a case report and review of the literature. Case Rep Otolaryngol. 2018;2018:1-4.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803-20.
Pavelin S, Becic K, Forempoher G, Mrklic I, Pogorelic Z, Titlic M, et al. Expression of Ki-67 and p53 in meningiomas. Neoplasma. 2013;60(5):480-5.
Kayaselçuk F, Zorludemir S, Bal N, Erdogan B, Erdogan S, Erman T. The expression of survivin and Ki-67 in meningiomas: correlation with grade and clinical outcome. J Neurooncol. 2004;67(1-2):209-14.
Ivan ME, Cheng JS, Kaur G, Sughrue ME, Clark AJ, Kane AJ, et al. Association of morbidity with extent of resection and cavernous sinus invasion in sphenoid wing meningiomas. J Neurol Surg B Skull Base. 2012;73(1):76-83.
Blankenstein MA, Verheijen FM, Jacobs JM, Donker TH, van Duijnhoven MW, Thijssen JH. Occurrence, regulation, and significance of progesterone receptors in human meningioma. Steroids. 2000;65(10-11):795-800.
Degeneffe A, De Maertelaer V, De Witte O, Lefranc F. The association between meningioma and breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(6):e2318620.
Maiuri F, Mariniello G, De Divitiis O, Esposito F, Guadagno E, Teodonno G, et al. Progesterone receptor expression in meningiomas: pathological and prognostic implications. Front Oncol. 2021;11:611218.
Agopiantz M, Carnot M, Denis C, Martin E, Gauchotte G. Hormone receptor expression in meningiomas: a systematic review. Cancers (Basel). 2023;15(3):980.
Strik HM, Strobelt I, Pietsch-Breitfeld B, Iglesias-Rozas JR, Will B, Meyermann R. The impact of progesterone receptor expression on relapse in the long-term clinical course of benign meningiomas. In Vivo. 2002;16(4):265-70.
Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008;79:574-80.
Fathi AR, Roelcke U. Meningioma. Curr Neurol Neurosci Rep. 2013;13(4):337.
Donnell MS, Meyer GA, Donegan WL. Estrogen-receptor protein in intracranial meningiomas. J Neurosurg. 1979;50(4):499-502.
Perrot-Applanat M, Groyer-Picard MT, Kujas M. Immunocytochemical study of progesterone receptor in human meningioma. Acta Neurochir (Wien). 1992;115(1-2):20-30.
Hilbig A, Barbosa-Coutinho LM. Meningiomas and hormonal receptors: immunohistochemical study in typical and non-typical tumors. Arq Neuropsiquiatr. 1998;56(2):193-9.
Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M. The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol. 2004;57(10):1033-7.
Cahill DW, Bashirelahi N, Solomon LW, Dalton T, Salcman M, Ducker TB. Estrogen and progesterone receptors in meningiomas. J Neurosurg. 1984;60(5):985-93.
Brandis A, Mirzai S, Tatagiba M, Walter GF, Samii M, Ostertag H. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features. Neurosurgery. 1993;33(2):212-8.
Maiuri F, De Caro MDB, Esposito F, Cappabianca P, Strazzullo V, Pettinato G, et al. Recurrences of meningiomas: predictive value of pathological features and hormonal and growth factors. J Neurooncol. 2007;82(1):63-8.
Shayanfar N, Mashayekhi M, Mohammadpour M. Expression of progesterone receptor and proliferative marker Ki-67 in various grades of meningioma. Acta Med Iran. 2010;48(3):142-7.
Fewings PE, Battersby RD, Timperley WR. Long-term follow up of progesterone receptor status in benign meningioma: a prognostic indicator of recurrence? J Neurosurg. 2000;92(3):401-5.
Magill ST, Young JS, Chae R, Aghi MK, Theodosopoulos PV, McDermott MW. Relationship between tumor location, size, and WHO grade in meningioma. Neurosurg Focus. 2018;44(4):E4.
Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemie K, et al. Pathodiagnostic parameters for meningioma grading. J Clin Neurosci. 2008;15:1370-5.
Downloads
Published
How to Cite
Issue
Section
